Our data provide critical new evidence of involvement of the eNAMPT/TLR4 inflammatory cascade in NAFLD and strongly indicate the eNAMPT-neutralizing ALT-100 mAb therapy as a novel effective therapy in NAFLD to prevent progression to NASH and fibrosis. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatohepatitis.